Stock Events

T2 Biosystems 

$4.79
311
-$0.13-2.63% Today

Statistics

Day High
4.84
Day Low
4.79
52W High
-
52W Low
-
Volume
399
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-4
-2.69
-1.39
-0.08
Expected EPS
-2.27
Actual EPS
-2.66

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A57.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap3.76B
Guardant Health, Inc. specializes in liquid biopsies and cancer diagnostics, directly competing with T2's diagnostic solutions in the oncology sector.
Hologic
HOLX
Mkt Cap18.23B
Hologic, Inc. offers diagnostics, medical imaging systems, and surgical products that compete in the broader diagnostics and women's health market alongside T2 Biosystems.
QuidelOrtho
QDEL
Mkt Cap2.32B
Quidel Corporation specializes in diagnostic healthcare products, including rapid diagnostic testing, a direct market competitor to T2 Biosystems.
Bio-Rad Laboratories
BIO
Mkt Cap8.45B
Bio-Rad Laboratories, Inc. provides a wide range of products and systems used for diagnostics and research, competing in the diagnostics market.
Dexcom
DXCM
Mkt Cap44.41B
DexCom, Inc. focuses on glucose monitoring systems, competing in the broader market of medical diagnostics and monitoring, relevant to T2 Biosystems' market.
Illumina
ILMN
Mkt Cap18.24B
Illumina, Inc. offers sequencing and array-based solutions for genetic analysis, competing in the genomics space relevant to T2's diagnostic applications.
Abbott Laboratories
ABT
Mkt Cap177.49B
Abbott Laboratories operates in multiple segments including diagnostics, medical devices, and nutrition, competing across several areas with T2 Biosystems.
Thermo Fisher Scientific
TMO
Mkt Cap203.97B
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics, competing broadly in the life sciences and diagnostics sectors.

About

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Show more...
CEO
John Sperzel
Employees
113
Country
US
ISIN
US89853L3024
WKN
000A3DXLT

Listings